With all due respect ringwraith HTW is completely different from...

With all due respect ringwraith HTW is completely different from SBN.

I held HTW for about 2 years (lost about 12%) so I know the company very well, and their business model is
completely dissimilar.

The LVAD is a potential market leader, and if HTW ever get their MVAD through clinical trials and implanted in patients then they will be the next Cochlear, with a device that will transform the way people live, and a patent that will transform the lives of investors. But that is many years away.

SBN are selling saliva tests in boxes of 10 for a few dollars, and need to build market awareness and get their sales & distribution network pumping to develop massive volume.

Personally I think that SBN's greatest future lies in their IP. Now that it's been successully defended and subsequently licensed SBN is in a much stronger position than they were when they released the last quarterly.

Looking at a re-entry, and have changed my sentiment to match.

All IMO only of course.